Diarrhea on Ozempic (semaglutide 0.5-2 mg): Incidence, Severity, and Realistic Expectations

How common is diarrhea on Ozempic?

In the Ozempic label's pool of two placebo-controlled trials in adults with type 2 diabetes, 262 people received placebo, 260 received 0.5 mg and 261 received 1 mg; mean Ozempic exposure was 32.9 weeks [1]. Diarrhea was reported by 1.9% on placebo, 8.5% at 0.5 mg and 8.8% at 1 mg, roughly four to five times the placebo rate [1].

Two things stand out. First, doubling the dose from 0.5 mg to 1 mg barely changed the diarrhea rate [1]. Second, some diarrhea happens without the drug at all: the placebo arm still reported it in about 1 in 50 people [1].

Diarrhea is not the most common digestive complaint. Gastrointestinal reactions as a whole occurred in 15.3% on placebo, 32.7% at 0.5 mg and 36.4% at 1 mg, and nausea was the most frequent individual reaction (6.1%, 15.8% and 20.3% respectively) [1]. In the label's larger pool of seven placebo- and active-controlled trials (3,150 patients treated with Ozempic, mean 44.9 weeks), the types and frequencies of common adverse reactions were similar to the smaller pool [1].

These trials enrolled adults with type 2 diabetes, and Ozempic has no weight-loss indication [1].

Does 2 mg cause more diarrhea than 1 mg?

A 40-week trial of 959 patients added Ozempic 1 mg or 2 mg to metformin with or without a sulfonylurea. At 2 mg, gastrointestinal reactions overall were reported by 34% of patients, versus 30.8% at 1 mg, and the label reports that no new safety signals were identified [1]. The Ozempic label does not give a separate diarrhea rate for this comparison [1].

What other semaglutide studies show about diarrhea

A 2024 review in JAMA of obesity medications reports diarrhea in 21% to 30% of patients for the hormone-based drugs it covers (liraglutide, semaglutide and tirzepatide), alongside nausea in 28% to 44% [2]. Those figures pool three drugs at their weight-management doses, so they are not Ozempic numbers at 0.5 to 2 mg.

A meta-analysis of nine randomized trials in people with overweight or obesity and no diabetes found semaglutide about doubled the odds of diarrhea compared with placebo (odds ratio 2.10), across 11,641 people given semaglutide and 10,479 given placebo [3]. A separate 40-week head-to-head trial in 1,879 adults with type 2 diabetes recorded diarrhea in 12% of those taking semaglutide 1 mg [4]. A 2025 review of GLP-1-based obesity therapy notes that gastrointestinal adverse events, diarrhea among them, often can be mitigated by slow up-titration [5].

How severe does it get?

The label's severity figure is for severe gastrointestinal reactions as a group rather than for diarrhea alone: 0.4% of patients on 0.5 mg and 0.8% on 1 mg, versus 0% on placebo, and the label says GI reactions with Ozempic can sometimes be severe [1]. It does not break diarrhea into mild, moderate and severe grades.

Severe abdominal pain is a different signal from loose stools. The label's pancreatitis warning describes persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, and says to discontinue Ozempic if pancreatitis is suspected [1].

When does it start, and does each dose increase bring it back?

The label states that the majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation [1]. Ozempic is titrated in stages: 0.25 mg weekly for 4 weeks (not a maintenance dose), then 0.5 mg, with increases to 1 mg and then 2 mg only after at least 4 weeks on the current dose [1]. The label gives no figure for how long a single episode lasts, and it does not report whether each dose increase brings diarrhea back [1].

Dehydration and kidney risk

The label's kidney warning concerns fluid loss from GI reactions, diarrhea included. It describes postmarketing reports of acute kidney injury, some requiring hemodialysis, with the majority of reported events in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea, and it says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1]. No dose adjustment is recommended for renal impairment [1].

Does age change the risk?

The Ozempic label does not give diarrhea rates by age. It reports no overall differences in safety or efficacy between patients 65 and older and younger patients, though it says greater sensitivity in some older individuals cannot be ruled out [1].